The U.S. Food and Drug Administration on Tuesday approved Sage Therapeutics Inc’s drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother’s ability to care for herself or her baby.
Latest posts by Reuters News (see all)
- Global stocks, yields dip with Fed meeting on tap - June 17, 2019
- Egyptian authorities refuse Mursi’s burial in family cemetery: son - June 17, 2019
- ‘Horror movie’ sex cult hid in ‘cookie cutter’ New York suburb: prosecutor - June 17, 2019